213 related articles for article (PubMed ID: 18442862)
1. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders.
Hallschmid M; Benedict C; Schultes B; Perras B; Fehm HL; Kern W; Born J
Regul Pept; 2008 Aug; 149(1-3):79-83. PubMed ID: 18442862
[TBL] [Abstract][Full Text] [Related]
2. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man.
Hallschmid M; Benedict C; Born J; Fehm HL; Kern W
Physiol Behav; 2004 Oct; 83(1):55-64. PubMed ID: 15501491
[TBL] [Abstract][Full Text] [Related]
3. Targeting metabolic and cognitive pathways of the CNS by intranasal insulin administration.
Hallschmid M; Benedict C; Born J; Kern W
Expert Opin Drug Deliv; 2007 Jul; 4(4):319-22. PubMed ID: 17683246
[TBL] [Abstract][Full Text] [Related]
4. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans.
Fehm HL; Smolnik R; Kern W; McGregor GP; Bickel U; Born J
J Clin Endocrinol Metab; 2001 Mar; 86(3):1144-8. PubMed ID: 11238499
[TBL] [Abstract][Full Text] [Related]
5. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue.
Wellhöner P; Hörster R; Jacobs F; Sayk F; Lehnert H; Dodt C
Int J Obes (Lond); 2012 May; 36(5):703-8. PubMed ID: 21629206
[TBL] [Abstract][Full Text] [Related]
6. Event-related brain potentials and working memory function in healthy humans after single-dose and prolonged intranasal administration of adrenocorticotropin 4-10 and desacetyl-alpha-melanocyte stimulating hormone.
Smolnik R; Perras B; Molle M; Fehm HL; Born J
J Clin Psychopharmacol; 2000 Aug; 20(4):445-54. PubMed ID: 10917406
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Neuropeptide Administration To Target the Human Brain in Health and Disease.
Spetter MS; Hallschmid M
Mol Pharm; 2015 Aug; 12(8):2767-80. PubMed ID: 25880274
[TBL] [Abstract][Full Text] [Related]
8. Obese men respond to cognitive but not to catabolic brain insulin signaling.
Hallschmid M; Benedict C; Schultes B; Born J; Kern W
Int J Obes (Lond); 2008 Feb; 32(2):275-82. PubMed ID: 17848936
[TBL] [Abstract][Full Text] [Related]
9. Overweight humans are resistant to the weight-reducing effects of melanocortin4-10.
Hallschmid M; Smolnik R; McGregor G; Born J; Fehm HL
J Clin Endocrinol Metab; 2006 Feb; 91(2):522-5. PubMed ID: 16317061
[TBL] [Abstract][Full Text] [Related]
10. Brain potentials and attention after acute and subchronic intranasal administration ofACTH 4-10 and desacetyl-alpha-MSH in humans.
Smolnik R; Mölle M; Fehm HL; Born J
Neuroendocrinology; 1999 Jul; 70(1):63-72. PubMed ID: 10420094
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism.
Ott V; Benedict C; Schultes B; Born J; Hallschmid M
Diabetes Obes Metab; 2012 Mar; 14(3):214-21. PubMed ID: 21883804
[TBL] [Abstract][Full Text] [Related]
12. Altered glucose homeostasis in proopiomelanocortin-null mouse mutants lacking central and peripheral melanocortin.
Hochgeschwender U; Costa JL; Reed P; Bui S; Brennan MB
Endocrinology; 2003 Dec; 144(12):5194-202. PubMed ID: 12970157
[TBL] [Abstract][Full Text] [Related]
13. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.
Benedict C; Frey WH; Schiöth HB; Schultes B; Born J; Hallschmid M
Exp Gerontol; 2011; 46(2-3):112-5. PubMed ID: 20849944
[TBL] [Abstract][Full Text] [Related]
14. Intranasal insulin to improve memory function in humans.
Benedict C; Hallschmid M; Schultes B; Born J; Kern W
Neuroendocrinology; 2007; 86(2):136-42. PubMed ID: 17643054
[TBL] [Abstract][Full Text] [Related]
15. Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist.
Kim RY; Shin SW; Kim BJ; Lee W; Baik JH
Biochem Biophys Res Commun; 2005 Apr; 329(4):1178-85. PubMed ID: 15766551
[TBL] [Abstract][Full Text] [Related]
16. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology?
Fehm HL; Perras B; Smolnik R; Kern W; Born J
Eur J Pharmacol; 2000 Sep; 405(1-3):43-54. PubMed ID: 11033313
[TBL] [Abstract][Full Text] [Related]
17. Role of central melanocortin signaling in eating disorders.
Lu XY
Psychopharmacol Bull; 2001; 35(4):45-65. PubMed ID: 12397856
[TBL] [Abstract][Full Text] [Related]
18. Effects of neuropeptides and leptin on nutrient partitioning: dysregulations in obesity.
Jeanrenaud B; Rohner-Jeanrenaud F
Annu Rev Med; 2001; 52():339-51. PubMed ID: 11160783
[TBL] [Abstract][Full Text] [Related]
19. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans.
Stockhorst U; de Fries D; Steingrueber HJ; Scherbaum WA
Physiol Behav; 2004 Oct; 83(1):47-54. PubMed ID: 15501490
[TBL] [Abstract][Full Text] [Related]
20. New ligands for melanocortin receptors.
Kaelin CB; Candille SI; Yu B; Jackson P; Thompson DA; Nix MA; Binkley J; Millhauser GL; Barsh GS
Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S19-27. PubMed ID: 19136986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
